All In Biotech

Drug Trial Radar · NCT00063804

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Not stated

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Sponsor type
NIH
Collaborators
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
First posted
Jul 8, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who have developed resistance to or are unable to take other anti-HIV drugs. This study will evaluate the safety of different doses of AMD070 along with AMD070 boosted with ritonavir (RTV) in HIV uninfected men.

Conditions

  • HIV Infections

Interventions

  • RitonavirDrug

  • AMD070Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AMD070 pharmacokinetic (PK) parameters under three conditions, and the within-volunteer differences between them
  2. Steady-state RTV PK parameters
  3. Grade 3 and 4 adverse effects, as defined by the protocol

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Adult AIDS CRS

    Baltimore, Maryland

  • University of Washington AIDS CRS

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.